|

TQB2102 for injection Clinical Trials

6 actively recruiting trials

▼ -1 trial since June 2026

Pipeline

Phase 2: 3Phase 3: 2Phase 1/2: 1

Top Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.6

Indications

Cancer6
Breast Cancer3
Gynecological Tumors1
Biliary Tract Cancer1
HER2-positive Breast Cancer1

Other6 trials

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Phase 3

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Phase 3

A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

Phase 2

A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Phase 2

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Phase 1/2

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.